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INTRODUCTION & BURDEN 
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1887, Noccard-Mollereau, bovine mastitis 
1933, Group B Antigen  
1964, severe neonatal sepsis, Eickhoff et al N Eng 
J med 
Ø 	  	  1970,	  N°1	  in	  neonatal	  infec/ons	  




10 capsular serotypes (Ia, Ib, II-IX) 	  
 
Streptococcus agalactiae or GBS 
Rebecca Lancefield 1895-1981 
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1887, Noccard-Mollereau, bovine mastitis 
1933, Group B Antigen  
1964, severe neonatal sepsis, Eickhoff et al N Eng 
J med 
Ø 	  	  1970,	  N°1	  in	  neonatal	  infec/ons	  
Streptococcus agalactiae or GBS 
 Streptococcus agalactiae clones infecting 
humans were selected and fixed through the 
extensive use of tetracycline  
 
•  Genome-based phylogeny reveals the expansion of a few 
clones 
•  Human GBS belong mainly to a small number of TcR clones   
V.Dacunha, MR.Davies, …, C.Poyart and P.Glaser 
In Nat Commun. 2014 Aug 4;5:4544. doi: 10.1038/ncomms5544. 
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Group B streptococcal diseases in 
neonates	  
 
§  Since the 1970s, leading cause of life-
threatening infections in newborns 
§  Neonatal illness/death 
§  Long-term disabilities 
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80 % EOD	

LOD             & VLOD	






80-90 % occur before  24 h	

§  Since the 1970s, leading cause of life-
threatening infections in newborns 
§  Neonatal illness/death 
§  Long-term disabilities 
A. Schuchat, Clin Microb Rev 
1998;11:497-513 
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Group B streptococcal diseases in 
neonates	  
 
§  Since the 1970s, leading cause of life-
threatening infections in newborns 
§  Neonatal illness/death 




     0.3-3 per 1,000 live birth 
 
LOD  
    0.4-0.5 per 1,000 live birth 
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GBS colonized mothers 





40 - 60 %!60 - 40 %!
GBS	  EOD	  ver/cal	  transmission	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40 - 60 %!60 - 40 %!
96	  -­‐	  98	  %	  
Asymptoma/c	  
GBS	  EOD	  ver/cal	  transmission	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40 - 60 %!
2 - 4 %!
GBS EOD 
(+ 50% no RF) 
60 - 40 %!









GBS	  EOD	  ver/cal	  transmission	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Stages in the pathogenesis of GBS 




adhesion to epithelial cells different 










-  C5a peptidase 
-  ….. Bacteria 
Peptidoglycan 
β-hemolysin, … 
IL1, IL6, TNF α, 
PGE2, TxA2 ,   
Brain barrier 




Phagocytes cells, CPS 
Antibodies, Complement 
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Stages in the pathogenesis 
of GBS neonatal EOD 
GBS surface proteins as ajor determinants for meningeal tropism  
Tazi A et al. 2011 Curr Op Microbiology - http://dx.doi.org/10.1051/medsci/2011274010 
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PREVENTION STRATEGIES FOR 
GBS PERINATAL DISEASE 
	  	  	  	   I N 
¤  Intrapartum antibioprophylaxis (IAP) 
¤  Immunoprophylaxis   
Key strategy 
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Stages in the pathogenesis of GBS 
neonatal EOD : Bacterial & individual factors 
GBS  
pathogenesis 
Colonization : adhesion to epithelial cells 
different virulence factors (pili, scpB, …) 
 Intrapartum  antibioprophylaxis 
> 4 (2) hours before delivery 
 
Highly effective in preventing GBS EOD (1st clinical trials in late 80s) 
Preventing 
transmission  
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Stages in the pathogenesis of GBS 
neonatal EOD : Bacterial & individual factors 
GBS  
pathogenesis 
Colonization : adhesion to epithelial cells 















« nearly within reach » 
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  Impact of prevention practices 
  Early- and Late-onset GBS Diseases in 
the 1990s, U.S. 
   Consensus   
   guidelines: 
- Screening  
-Risk-based 
Group B Strep 
Association 
formed  
  1st ACOG & AAP 
   statements 
           CDC draft  
guidelines published 
S. Schrag, New Engl J Med 2000 
Schrag S. et al. N Engl J Med 2002; 347:233-9 
 
Screening >50%  
more effective  
than RF 
 
No effect on GBS LOD 
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  Impact of prevention practices 
  Early- and Late-onset GBS Diseases, U.S. 
Incidence of early- and late-onset invasive group B streptococcal disease in 
















































department of health and human services
Centers for Disease Control and Prevention
Recommendations and Reports November 19, 2010 / Vol. 59 / No. RR-10
Morbidity and Mortality Weekly Report
www.cdc.gov/mmwr
Prevention of Perinatal Group B 
Streptococcal Disease
Revised Guidelines from CDC, 2010
Continuing Education Examination available at http://www.cdc.gov/mmwr/cme/conted.html
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European strategies 
for prevention of GBS EOD 
§  Intrapartum antibioprophylaxis recommended 
§ Screening-based strategy 
§  Spain, 1998, 2003, revised 2012 
§  France, 2001 
§  Belgium, 2003, revised 2015 
§  Germany, 1996, revised 2008 
§  Switzerland, 2007  
§ Risk-based strategy 
§  UK, the Netherlands, Denmark 
 
§  No guidelines 
§  Bulgaria, … 
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Universal screening-based strategy for 
prevention of GBS perinatal disease (Be SHC 2003) 
Vagino-rectal GBS screening culture  at 35-37 weeks of gestation  
 
For ALL pregnant women 
> 1 Risk factor:  
   - Intrapartum fever > 38°C*** 
   -  ROM > 18 hrs 




























if NO! if YES!
Unless patient had a previous infant with GBS invasive disease  
 or GBS bacteriuria during current pregnacy 
 or delivery occurs < 37 weeks’ gestation * 
GBS Neg 
if  YES!
GBS POS Not done, incomplete or 
unknown GBS result 
! Facultative !  
Intrapartum rapid GBS  test** 
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P. De Mol
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Concerns : Clinically relevant 
antimicrobial resistance 
¤   Increase of resistance to erythromycin and 
clindamycin 
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Resistance to macrolides/lincosamides 
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Resistance to macrolides/lincosamides 
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Concerns : Clinically relevant 
antimicrobial resistance 
¤   Increase of resistance to erythromycin and 
clindamycin 
	  	  	  	  	  	  
§  Revised guidelines for microbiological 
detection of clindamycin resistance  
(SHC 2015) 
§  Antimicrobial susceptibility testing on all GBS 
§  Dtest recommended 
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Concerns : Clinically relevant 
antimicrobial resistance 
¤  Reduced susceptibility to penicillin 
§  Very few « not S » isolates recently characterized 
in Japan         
§  Mutation in pbp genes, especially pbp2x  
§  MIC= 0.25 -1 mg/L (but higher MIC to Ceph. !) 
§  No clinical impact ? 
Noriyuki Nagano et al, AAC 2008 
§  Very few in the U.S., Canada 
§  Possibly unrecognized by standard antimicrobial 
susceptibility methods  
 
	  	  	  	  	  	  
¤  All labs should send to reference lab 
¤  Any « non-S » isolate for confirmation 
¤  All invasive isolates for resistance surveillance 
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Other concerns 
Potential adverse / unintended consequences of 
prophylaxis 
§  Allergies 
§  Anaphylaxis occurs but extremely rare 
§  Changes in incidence or resistance of other 
pathogens causing EOD 
§  Data are complex … 
§  But most studies: stable rates of « other » sepsis 
§  Changes in GBS antimicrobial resistance 
§  Impact on newborn gut microbiota 
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Remaining burden of GBS EOD 
Missed opportunities 
In spite of universal screening prevention 
strategy 
In spite the great progress 
 Cases still occur 
§  Among remaining cases of EOD 
§  Some may be preventable cases 
§  Missed opportunities for (appropriate) IAP 
§  False negative screening 
Van Dyke MK, Phares CR, Lynfield R et al. N Engl J Med 2009 
CDC revised guidelines 2010 
Poyart C, Reglier-Poupet H, Tazi et al. Emerg Infect Dis 2008 
DEVANI project, unpublished data 2011 
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SCREENING  











Culture or non culture approach? 
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Antenatal GBS culture-based 
screening 
Goal of GBS screening 
To predict GBS vaginal (rectal) colonization at the 
time of delivery 
§ 	  Critical factors influencing accuracy 
§  Swabbed anatomic sites (distal vagina + rectum) 
§  Timing of sampling 




§  Non-culture  
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Culture-­‐based	  screening	  done	  1	  to	  5	  or	  >	  6	  weeks	  before	  
delivery	  (Yancey,	  860	  cases;	  Melin,	  531	  cases)	  
Not	  100	  %	  as	  
coloniza/on	  is	  dynamic	  
Yancey MK et al. Obstet Gynecol 1996;88:811-5 
Op/mal	  /me	  for	  screening	  
35-­‐37	  weeks	  gesta/on 
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Culture-­‐based	  screening	  done	  1	  to	  5	  or	  >	  6	  weeks	  before	  
delivery	  (Yancey,	  860	  cases;	  Melin,	  531	  cases)	  
Yancey MK et al. Obstet Gynecol 1996;88:811-5 
Op/mal	  /me	  for	  culture-­‐based	  screening	  
35-­‐37	  weeks	  gesta/on 
Melin, 13-16% GBS Pos 
PPV= 56% 
NPV= 95% 
or 5% False negative  
or 30% of  GBS pos in 
labor not detected with 
antenatal screening ! 
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Antenatal culture-based screening: 
Limiting factors 
§  Positive and negative predictive values 
§  False-negative results 
§  Failure of GBS culture  (reduced viability during transport, 
oral ATB, feminine hygiene) or new acquisition 
§  Up to 1/3 of GBS positive women at time of delivery 
Need for more accurate	  predictor	  of	  	  
intrapartum	  GBS	  vaginal	  coloniza/on	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From direct plating on blood agar 
Evolution of culture methods 	  
Use of selective enrichment broth (Lim broth, e.g.) 
§  To maximize the isolation of GBS 
§  To avoid overgrowth of other organisms 
 
Use of differential agar media 
Recommended by some European guidelines (+ CDC 2010) 
 
 1983, 1992                            2005       2007 
GRANADA 
(M.de la Rosa,JCM) 
Strepto B 
Select  
StreptoB ID  
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Which agar or which combination? 
+/- Blood agar 
 
Workload - costs - extra-testing - non β-hemolytic  
GBS detection  to be considered 
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§  WHEN   35-37 weeks 
§  WHO  ALL the pregnant women 
§  Specimen   Vaginal + rectal swab(s) 
§  Collection  WITHOUT speculum 
§  Transport  Transport/collection device/condition 
 (non nutritive medium: Amies/Stuart or Granada 
 like tube) (type of swab)(Length and T°) 
§  Request form  To specify prenatal « GBS » 
 screening  
§  Laboratory procedure 
Crucial conditions to optimize 
SCREENING 
(CDC 2010 - Belgian SCH 2003) 
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Transport-collection system & transport-storage condition 
§  Type of swab: Nylon flocked >> regular fiber swab 
Crucial conditions to optimize 
SCREENING 
eSwab® 
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Transport-collection system & storage condition 
 
§   Recommandations CDC, USA (2010)  
§  Non nutritive media: Amies or Stuart without charcoal 
§  Storage at 4°C or  RT 1-4 days 
§  Or Granada like tubes ?? 
§  Recommandations CSS, Belgium (2003) 
§  Non nutritive media: Amies or Stuart without charcoal 
§  Storage maximum 48h at 4°C 
Crucial conditions to optimize 
SCREENING 
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IMPROVEMENT OF TRANSPORT CONDITION OF 
SWABS FOR GROUP B STREPTOCOCCAL 
(GBS) SCREENING   
 P. Melin, M. Dodémont, G. Sarlet, R. Sacheli, J. Descy, C. Meex, 
P.Huynen, MP. Hayette 
National Reference Centre for GBS, University Hospital of Liège, Liège, Belgium 
To sustain viability 
Whatever is storage T° for a few days 
Use of a selective enrichment Lim broth as 
transport media 
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Results: 
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Transport conditions to be 
recommended for optimizing GBS 
antenatal screening 
 Belgian Health Superior Council, 2015 
§  Transport system 
§  Use of a selective enrichment Lim broth with a flocked swab 
 (BD, Copan, bioMérieux, i.e.) 
§  Transport and storage condition 
§  At RT° (up to 35°C)  
§  As soon as possible  
§  Viability sustained at least 4 days  
§  Remark 
§  If use of Amies or Stuart medium (non nutritive medium)  
§  To be processed as soon as possible within 24 hours (max 48 h)  
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Antenatal culture-based screening 
combined with amplification 
molecular methods 
Broth enrichment followed 
by amplification molecular 
assay  
q The Xpert GBS LB assay 
q The LAMP Illumigene GBS 
Assay 
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Alternative to GBS antenatal 
screening: intrapartum screening 
Theranostic approach 
Turnaround time 








30-45 minutes, 24 hrs/7 d, robust 
Benitz et al. 1999, Pediatrics, Vol 183 (6) 
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§  Inclusion of women without prenatal screening/care 
§  Identification of women with change of GBS status 
after 35-37 wks gestation 
§  Increased accuracy of vaginal GBS colonization 
status at time of labor & delivery 
 
Intrapartum screening theranostic 
approach: expected advantages 
IAP addressed to right target 
§  Reduction of inappropriate/unnecessary IAP 
§  Broader coverage of « at GBS risk women »  
Improvement of prevention  
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Real Time PCR for intrapartum 
screening 
§  Advance in PCR techniques & development of 
platforms 
§  BD GeneOhmTM Strep B Assay (+/- 1 hr) (in laboratory) 
§  Xpert GBS, Cepheid (35-45 min) (can be performed as a POCT)  
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Xpert GBS for intrapartum screening 
(selected paper amongst many others) 
Diagnostic Accuracy of a Rapid Real-Time Polymerase Chain 
Reaction Assay for Universal Intrapartum Group B Streptococcus 
Screening  
Najoua El Helali, Jean-Claude Nguyen, Aïcha Ly, Yves Giovangrandi and 
Ludovic Trinquart   
Clinical Infectious Diseases 2009;49:417–23 
 
§  968 Pregnant women  
§  Intrapartum Xpert GBS, Cepheid  (performed in lab) 
§  vs intrapartum culture      antenatal culture (French recom.) 
              (vaginal swab/CNA-BA) 
§  Sensitivity   98.5% 
§  Specificity   99.6% 
§  PPV     97.8%    PPV    58.3% 
§  NPV     99.7%    NPV    92.1% 
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Xpert GBS for intrapartum screening 
(selected paper amongst many others) 
Cost and effectiveness of intrapartum group B streptococcus 
polymerase chain reaction screening for term deliveries. 
El Helali N, Giovangrandi Y, Guyot K, Chevet K, Gutmann L, Durand-
Zaleski I 
Obstet Gynecol 2012 Apr;119 (4):822-9 
 
           2009               2010  
Antenatal screening    Xpert GBS intrapartum screening 
        Performed by midwives as a POCT !! 
11.7% GBS POS     16.7% GBS POS 
        Less GBS EOD & less severe 
 
                        Cost neutral per delivery 
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Real-­‐/me	  PCR,	  very	  promising,	  BUT	  …	  
§  Rapid, robust & accurate technology 
§  Still an expensive technology (specific equipment) 
§  Cost effective ?   
§  Need for more cost-effectiveness clinical study  
        è 2014 NRC GBS - CHULg & UIA 
	  	  	  	  	  	  
§  Logistic 
§  24 hours 7 days 
§  In the lab? 
§  In the obstetrical department as a POCT ? 
§  In combination with prenatal screening strategy ? 
§  CDC 2010 : for women with premature delivery or no prenatal care 
§  Drawback: no antimicrobial result  
§  In the future detection of R genes, but mixed microbiota ! 
P.Melin CHU of Liege – NRC for S.agalaciae (GBS) 
Rencontres de périnatalogie  - ULB – 24.02.2015 9 
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Revised	  Belgian	  guidelines	  
(Superior	  Health	  Council,	  2015)	  
(Neonatologists, obstetricians, microbiologists, midwives) 
Main recommendentions 
§  Universal antenatal screening at 35-37 wks gestation 
§  Lim broth as transport media 
§  Selective differential culture media 
§  Determination of clindamycin susceptibility (IgE mediated penicillin 
allergy) 
§  Universal screening at time of delivery could be used 
§  IF POCT with high PPV and NPV 
§  Real time PCR or other methods 
§  TAT < 1 hour 
§  In case of known IgE mediated penicillin allergic women  
§  Determination of clindamycin susceptibility for GBS positive screening 
§  IAP for all GBS positive pregnant women  
§  documented by antenatal testing (or intrapartum testing if 
performed) 
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Revised	  Belgian	  guidelines	  
(Superior	  Health	  Council,	  2015)	  
(Neonatologists, obstetricians, microbiologists, midwives) 
Main recommendentions 
§  Mahieu L, Langhendries JP, Cossey V, De Praeter C, Lepage P, 
Melin P.  
Management of the neonate at risk for early-onset Group B 
streptococcal disease (GBS EOD): new paediatric guidelines in 
Belgium.   
 
Acta Clin Belg. 2014 Oct;69(5):313-9.  
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TOWARDS A EUROPEAN 
CONSENSUS ? 
 
Conference held in June 2013, Florence, Italy 
 




Representing countries  
•  with screening-based IAP,  
•  with risk-based IAP strategies  
•  or nothing   
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Towards	  «	  European	  Consensus	  »	  




§  Universal screening at time of delivery 
§  POCT with high PPV and NPV 
§  Real time PCR or other methods 
§  TAT < 1 hour 
§  IAP for all GBS positive pregnant women  
§  documented by intrapartum testing (or late pregnancy test if 
performed) 
§  Late pregnancy prenatal screening in known penicillin allergic 
women  
§  Determination of clindamycin susceptibility if GBS positive screening 
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Towards	  «	  European	  Consensus	  »	  




§  Provisionally , for countries with antenatal screening 
§  Improved antenatal screening method 
§  Use of Lim broth for transportation 
§  Use of selective differential media 
	  	  	  	  	  	  
Di Renzo GC, Melin P, Berardi A, et al  
Intrapartum GBS screening and antibiotic prophylaxis: a European 
consensus conference.   
J Matern Fetal Neonatal Med. 2014 Aug 27:1-17  
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VACCINE 
	  	  	  	  VA CINE
Prevention of GBS EOD and LOD 
Prevention of maternal diseases 
P.Melin CHU of Liege – NRC for S.agalaciae (GBS) 
Rencontres de périnatalogie  - ULB – 24.02.2015 10 
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Background	  
§  Correlate between maternal low level off CPS 
type Ab at time of delivery and risk for 
development of GBS EOD  
Baker C et Kasper D, 1976, NEJM 
 
 Vaccine for pregnant women: 
 Likely the most effective, sustainable and cost 
effective approach 
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GBS Vaccines, since the 1980s   
Challenges 
Capsular polysaccharide vaccines 
§  10 serotypes 
§  Different distributions 
§  EOD, LOD, invasives infections in adults 
§  Geographically and along time 
§  Conjugated vaccines 
§  Multivalent vaccines Ia, Ib, (II), III and V 
§  Clinical studies (phases 1, 2 and 3) 
§  Immunogenicity 
§  Safety 
§  Efficacy: scheduled/ongoing 
Within reach ! 
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GBS Vaccines 
GBS Protein-based Vaccine 
§  Ag = Surface proteins 
§  Cross protection against different serotypes 
§  Better immunogenicity 
§  Humoral response T-cell dependent   
    = long lasting immunity 
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Protein-­‐based	  Vaccines	  
Protein  Protective Ab  associated serotypes 
  (in mouse) 
Alpha-like proteins   
    Alpha  Yes    Ia, Ib et II 
    Alp1      Ia 
    Rib  Yes    III 
    Alp2  Yes    V, VIII 
    Alp3  Yes    V, VIII 
Beta C protein  Yes    Ib 
C5a peptidase  Yes    All 
Sip (1999)  Yes    All 
BPS  Yes    All 
Sip = Surface Immunogenic Protein (Brodeur, Martin, Québec)  
BPS= Groupe B Protective surface Protein 
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Protein-based Vaccines 
Reverse vaccinology approach 
Knowledge of complete GBS genome 
 
§  Comparaison of genomes from 8 different 
GBS serotypes 
D.Maione et al, Science 2006 
§  312 surface proteins were cloned 
§  4  Provide a high protective humoral response in 
mouse 
§  Sip and 3 others 
§  The 3 other proteins = « pilus like structures » 
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GBS « pilus like structure » 
§  Highly immunogenic proteins 
§  Elicit protective and functional antibodies 
§  Virulence factor 
§  Adhesion 
§  Transcytose through cells 
	  	  	  	  VA CINE
P.Melin CHU of Liege – NRC for S.agalaciae (GBS) 
Rencontres de périnatalogie  - ULB – 24.02.2015 11 
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Vaccine 31S (2013) D1– D2
Contents lists available at ScienceDirect
Vaccine
jou rn al hom ep age: www.elsev ier .com/ locat e/vacc ine
Editorial
Introduction:  Addressing  the  challenge  of  group  B  streptococcal  disease
Towards the end of the 20th century, progress in vaccine devel-
opment technology led to the availability of conjugate vaccines
for the most common causes of bacterial sepsis and meningitis in
children including vaccines for Haemophilus influenzae type b, the
pneumococcus and meningococcus serotypes A, C, W-135 and Y
[1]. Recently a new vaccine for meningococcus serogroup B devel-
oped by reverse vaccinology has been approved by the EMA. These
advances in technology have been great advances in our ability to
prevent sepsis and meningitis in children.
On a parallel track, programmatic advances in the use of existing
vaccines have provided the opportunity to protect vulnerable pop-
ulations such as newborn infants and pregnant women. Although
maternal immunization with tetanus toxoid in developing coun-
tries has been recommended by WHO  for decades and has greatly
reduced the risk of neonatal tetanus, more recently immunization
of pregnant women has been recommended against influenza to
protect the mother and the infant [2]. In fact, influenza immuniza-
tion in pregnancy has been shown to have broad benefits to the
mother and infant including increased birth weight in infants born
to immunized mothers [2]. In addition, maternal pertussis immu-
nization during pregnancy is now routinely recommended in the
United States to protect newborns against this disease. Since infant
immunization with pertussis can not provide effective protection
to the infant until their second dose at four months of age and since
the highest morbidity and mortality of pertussis is in the first few
months of life, this was felt to be the only possible strategy to pro-
vide protection to these infants [3]. Importantly, these programs
have demonstrated not only that maternal immunization during
pregnancy is feasible, but also that it is a safe and effective vac-
cination strategy. However, the tetanus, influenza and pertussis
programs all have one thing in common: these programs utilize
vaccines that were developed and initially evaluated for use in
adults and older children and were then introduced into pregnant
women at a later date. To date, no vaccine has been approved and
licensed for use that has been specifically designed and targeted for
use in pregnant women.
With vaccine advances that have controlled or virtually elim-
inated the risk of Hib, pneumococcal and meningococcal disease
in children, the major cause of meningitis and sepsis in childhood
in developed countries and a major cause in all countries is now
the group B streptococcus or Streptococcus agalactiae (GBS). The
most widely recognized GBS disease occurs in newborns and young
infants with approximately half of this disease occurring within the
first hours of life (early onset disease) and the remainder occurring
after the first week but within the first 90 days (late onset disease).
The disease incidence varies by country but can be as high as 3 cases
per 1000 live births [4] with mortality ranging between 10 and 50%
even with modern neonatal intensive care [5]. It is important to
note that while programs which screen pregnant women for GBS
colonization and then institute intrapartum antibiotic prophylaxis
in those testing positive for GBS have been effective in reducing the
risk of early onset diseases in infants most notably in the US,  these
programs are not optimal both because the coordinated high level
of health care management is not available in developing countries
and importantly these programs only impact early onset GBS dis-
ease and have no effect on the remaining 50% of the total disease
burden in infants accounted for by late onset disease.
Moreover, there is increasing evidence that GBS is a cause
of maternal infections including urinary tract infections and
chorioamnionitis which result in maternal morbidity during preg-
nancy and are a risk factor for prematurity [6]. Recently it has been
demonstrated that selected strains of GBS lacking the hemolysin
repressor CovR/S accelerate failure of the amniotic barrier and
allow GBS to penetrate the chorioamniotic membrane barrier and
gain access to the fetus [7]. This provides a pathophysiologic basis
for the previously demonstrated ability of GBS  to cause maternal
chorioamnionitis as well as to gain access to the fetus and cause
early onset disease.
Thus a GBS vaccine administered to pregnant women during
pregnancy would have the potential to prevent the morbidity of
GBS infections in the mother with their associated risk of prematu-
rity as well as to protect the infant against both early and late onset
disease through passive acquired antibody.
It has been known for some time that antibody against the GBS
capsular polysaccharide in mothers is correlated with decreased
risk of disease in their infants [8]. This protection is serotype spe-
cific with most disease being due to serotypes Ia, Ib, III and to a
lesser extent serotype V. Novartis Vaccines has developed a vac-
cine containing CRM197 conjugates of capsular polysaccharides Ia,
Ib and III. This vaccine has been shown to be safe and immuno-
genic in both pregnant and non-pregnant women and to provide
IgG anti-capsular antibody to infants born to immunized pregnant
women through transplacental passive transfer (Novartis Vaccines
and Diagnostics, unpublished data). Preparation for a phase III effi-
cacy trial to evaluate the effectiveness of maternal immunization
with a trivalent GBS glycol-conjugate in the prevention of both early
and late onset GBS disease in their newborns is now underway.
In July 2012, a symposium was  held in Siena, Italy to discuss
the nature of Group B Streptococcal disease in the newborn, to
review current global disease burden and to discuss the need to
effective interventions which would be applicable in both devel-
oped and developing countries. The papers in this supplement to
0264-410X/$ – see front matter ©  2013 Elsevier Ltd. All rights reserved.
http://dx.doi.org/10.1016/j.vaccine.2013.06.072
•  Introduction, Rappuoli & Black 
•  GBS Revi w, Carol Baker 
•  Overview GBS epi emiology, Paul Heath 
•  GBS epidemi  and vaccine needs, Melin &  Efstratiou  
•  GBS epidemiolog  in dev lo ping c untries 
•  IAP in USA et Vaccine implications, S.Schrag & Verani 
•  GBS maternal vaccines Past Present and Future, Chen & Kasper 
•  GBS Public awareness etc 
•  Pr vention  through Vaccinatio , M. Edwards 
•  GBS Vacci ation in pregnancy, P. F rrieri 
•  GBS vaccine Phas  III trial 
Vaccine 31S, 2013 
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CONCLUSION 
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In Europe, s glob lly	  
Neonatal GBS diseases  
§  EOD and LOD, a global health concern 
§  IAP efficient for prevention of EOD 
§  Best strategy still a matter of debate  
§  Not 100% efficient 
§  No effect on LOD 
§  IAP not widely recommended 
§  New tools to improve GBS detection 
§  Toward a European consensus 
GBS vaccine eagerly expected  
§  Appears to be within reach  
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Summary	  
“Screening” Prevention strategies 
 
§  Culture-based GBS antenatal 
screening 
§  False +/False - 
§  To optimize critical factors 
§  Improved by selective differential agars 
§  Expected improvement from transport system 
§    
§  Rapid intrapartum screening 
§  Real time PCR 
§  Yes but costs, logistic, … 
§  Need for more clinical and cost effectiveness trials 
§  No result for clindamycin susceptibility 
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Thank you ! 
